U.S. markets closed
  • S&P 500

    4,305.20
    +8.06 (+0.19%)
     
  • Dow 30

    34,152.01
    +239.57 (+0.71%)
     
  • Nasdaq

    13,102.55
    -25.50 (-0.19%)
     
  • Russell 2000

    2,020.53
    -0.82 (-0.04%)
     
  • Crude Oil

    86.87
    -2.54 (-2.84%)
     
  • Gold

    1,790.60
    -7.50 (-0.42%)
     
  • Silver

    20.10
    -0.17 (-0.85%)
     
  • EUR/USD

    1.0173
    +0.0008 (+0.08%)
     
  • 10-Yr Bond

    2.8240
    +0.0330 (+1.18%)
     
  • GBP/USD

    1.2098
    +0.0039 (+0.33%)
     
  • USD/JPY

    134.2400
    +0.9680 (+0.73%)
     
  • BTC-USD

    23,943.78
    -137.35 (-0.57%)
     
  • CMC Crypto 200

    568.96
    -2.96 (-0.52%)
     
  • FTSE 100

    7,536.06
    +26.91 (+0.36%)
     
  • Nikkei 225

    28,868.91
    -2.87 (-0.01%)
     

Aurora Cannabis: Analysts’ Recommendations in December

Aurora Cannabis: Analysts’ Recommendations in December
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Aurora Cannabis (ACB) (ACBFF) has been an underperformer in the cannabis sector, especially compared to its peers (HMMJ) including Canopy Growth (WEED), HEXO (HEXO), and Cronos Group (CRON). The company closed at 7.4 Canadian dollars on December 18, which was nearly 34.7% lower YTD (year-to-date). Let’s look at how analysts’ recommendations and target price changed month-over-month.